BeiGene - BGNE Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BGNE shares.
View BGNE analyst ratings or view top-rated stocks.

6 brokers have issued 12-month price targets for BeiGene's shares. Their BGNE share price forecasts range from $213.00 to $350.00. On average, they expect the company's stock price to reach $292.86 in the next year. This suggests a possible upside of 34.8% from the stock's current price.
View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts.

BeiGene's stock was trading at $219.94 at the start of the year. Since then, BGNE shares have decreased by 1.2% and is now trading at $217.28.
View the best growth stocks for 2023 here.

BeiGene saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,180,000 shares, an increase of 7.9% from the February 28th total of 2,020,000 shares. Based on an average daily trading volume, of 244,200 shares, the short-interest ratio is currently 8.9 days.
View BeiGene's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our BGNE earnings forecast.

BeiGene, Ltd. (NASDAQ:BGNE) posted its earnings results on Monday, February, 27th. The company reported ($4.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.18) by $0.11. The firm earned $380.10 million during the quarter, compared to the consensus estimate of $388.17 million. BeiGene had a negative trailing twelve-month return on equity of 39.72% and a negative net margin of 141.86%. The company's revenue was up 77.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($6.22) EPS.

ETFs with the largest weight of BeiGene (NASDAQ:BGNE) stock in their portfolio include Direxion mRNA ETF (MSGR), Loncar Cancer Immunotherapy ETF (CNCR), VanEck Biotech ETF (BBH), Loncar China Biopharma ETF (CHNA), Virtus LifeSci Biotech Products ETF (BBP), iShares Biotechnology ETF (IBB), Global X Aging Population ETF (AGNG) and B.A.D. Etf (BAD).

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

BeiGene trades on the NASDAQ under the ticker symbol "BGNE."

BeiGene's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (3.27%), Price T Rowe Associates Inc. MD (0.44%), Bank of America Corp DE (0.30%), Geode Capital Management LLC (0.24%), Fairmount Funds Management LLC (0.23%) and Morgan Stanley (0.17%). Insiders that own company stock include Amgen Inc, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends.

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BGNE stock can currently be purchased for approximately $217.28.

BeiGene (NASDAQ:BGNE) has a market capitalization of $22.68 billion and generates $1.42 billion in revenue each year. The company earns $-2,003,810,000.00 in net income (profit) each year or ($19.48) on an earnings per share basis.

The company employs 9,200 workers across the globe.

BeiGene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The official website for the company is www.beigene.com. The company can be reached via phone at (345) 949-4123 or via email at ir@beigene.com.